Enjoy complimentary customisation on priority with our Enterprise License!
Market research analysts at Technavio predict that the global short bowel syndrome (SBS) market will grow steadily at a CAGR of around 26% by 2021. This market research analysis identifies the special drug designations as one of the primary growth factors for this market. The market is dominated by few drugs and the special designation provides more potential for revenue generation and geographical expansion. The designation provides the vendors with benefits such as the extension of patent exclusivity period to address the need for an orphan drug, tax credits up to half of R&D costs, and exemption from US FDA application fees, consequently, reducing the vendors burden in developing a product for a rare disease. The R&D expenses are high for such novel molecules, as a result, a special designation encourages the vendors to conduct such R&D, which otherwise would make the molecule economically unviable.
The market research report identifies the increased awareness of gastrointestinal (GI) disorders as one of the key trends behind the growth of this market. Many government bodies, pharmaceutical companies, health ministries, and NGOs conduct health programs and camps to educate the people and raise awareness. Vendors distribute free samples and kits with the aim of educating the people and promoting their drugs. The increasing public awareness about the generic disorders or bowel related disorders is influencing the vendors and authorities to provide adequate knowledge and information to the segment with limited knowledge. The increasing awareness about the overall bowel health maintenance and remedial measures will benefit this niche market for SBS in terms of patient compliance and will increase sbs market revenue.
The SBS market is dominated by few key players. To gain a competitive edge and improve their market shares, the vendors in the market are increasingly focusing on following strategies such as mergers and acquisitions and distribution through partnerships and are also concentrating on attending medical trade shows.
The leading vendors in the market are -
The other prominent vendors in the market are Ardelyx, Naia Pharmaceuticals, Nutrinia, OxThera, Sancilio Pharmaceuticals, and Zealand Pharma.
During 2016, the parental route segment accounted for the major shares and dominated the SBS market. Factors such as the rapid action mechanism of the drug and the prolonged action result contribute to the growth of this market segment in the coming years. In the parental route, the drug is administered intravenously, subcutaneously, intrathecally, or through intramuscular routes and is applied when the oral route of drug administration is ineffective.
During 2016, the SBS market was dominated by the GLP-2 segment. This drug class improves intestinal absorption of fluids and nutrients, thereby reducing the frequency and volume of PN, consequently being the most recommended drugs for short bowel syndrome. Factors such as the ability to induce adaption after resection and intestinotrophic growth will fuel the growth of this market segment.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Orphan drug designation
PART 06: Pipeline landscape
PART 07: Market landscape
PART 08: Market segmentation by route of administration (ROA)
PART 09: Market segmentation by drug class
PART 10: Geographical segmentation
PART 11: Decision framework
PART 12: Drivers and challenges
PART 13: Market trends
PART 14: Vendor landscape
PART 15: Key vendor analysis
PART 16: Appendix
Tags: colon cancer, stomach cancer, cancer test, cancer surgery, medical devices market growth, healthcare segmentation analysis,
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.